Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.53
AMAG's Cash-to-Debt is ranked lower than
87% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. AMAG: 0.53 )
Ranked among companies with meaningful Cash-to-Debt only.
AMAG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.53
Equity-to-Asset 0.38
AMAG's Equity-to-Asset is ranked lower than
77% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. AMAG: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
AMAG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.72 Max: 0.98
Current: 0.38
0.33
0.98
Interest Coverage 1.08
AMAG's Interest Coverage is ranked lower than
98% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMAG: 1.08 )
Ranked among companies with meaningful Interest Coverage only.
AMAG' s Interest Coverage Range Over the Past 10 Years
Min: 1.08  Med: No Debt Max: No Debt
Current: 1.08
Piotroski F-Score: 4
Altman Z-Score: 0.64
Beneish M-Score: -2.94
WACC vs ROIC
4.51%
5.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 14.82
AMAG's Operating Margin % is ranked higher than
84% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. AMAG: 14.82 )
Ranked among companies with meaningful Operating Margin % only.
AMAG' s Operating Margin % Range Over the Past 10 Years
Min: -4107.64  Med: -72.84 Max: 26.59
Current: 14.82
-4107.64
26.59
Net Margin % -0.47
AMAG's Net Margin % is ranked higher than
70% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. AMAG: -0.47 )
Ranked among companies with meaningful Net Margin % only.
AMAG' s Net Margin % Range Over the Past 10 Years
Min: -3696.96  Med: -71.06 Max: 109.19
Current: -0.47
-3696.96
109.19
ROE % -0.27
AMAG's ROE % is ranked higher than
76% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. AMAG: -0.27 )
Ranked among companies with meaningful ROE % only.
AMAG' s ROE % Range Over the Past 10 Years
Min: -52.39  Med: -15.27 Max: 42.96
Current: -0.27
-52.39
42.96
ROA % -0.10
AMAG's ROA % is ranked higher than
78% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. AMAG: -0.10 )
Ranked among companies with meaningful ROA % only.
AMAG' s ROA % Range Over the Past 10 Years
Min: -44.82  Med: -13.1 Max: 16.42
Current: -0.1
-44.82
16.42
ROC (Joel Greenblatt) % 288.57
AMAG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. AMAG: 288.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMAG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1009.91  Med: -510.9 Max: 475.79
Current: 288.57
-1009.91
475.79
3-Year Revenue Growth Rate 60.80
AMAG's 3-Year Revenue Growth Rate is ranked higher than
89% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. AMAG: 60.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMAG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -31  Med: 19.5 Max: 193.8
Current: 60.8
-31
193.8
3-Year EPS without NRI Growth Rate -45.80
AMAG's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. AMAG: -45.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMAG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.7  Med: -2.4 Max: 78.1
Current: -45.8
-51.7
78.1
GuruFocus has detected 3 Warning Signs with AMAG Pharmaceuticals Inc $AMAG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMAG's 10-Y Financials

Financials (Next Earnings Date: 2017-05-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AMAG Guru Trades in Q1 2016

Paul Tudor Jones 286,200 sh (New)
Jim Simons Sold Out
Scott Black Sold Out
Joel Greenblatt 204,184 sh (-5.67%)
» More
Q2 2016

AMAG Guru Trades in Q2 2016

Steven Cohen 446,300 sh (New)
Joel Greenblatt 411,912 sh (+101.74%)
Paul Tudor Jones 375,500 sh (+31.20%)
» More
Q3 2016

AMAG Guru Trades in Q3 2016

Joel Greenblatt 507,809 sh (+23.28%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q4 2016

AMAG Guru Trades in Q4 2016

Paul Tudor Jones 11,200 sh (New)
Jim Simons 513,500 sh (New)
Joel Greenblatt 600,584 sh (+18.27%)
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:INSY, NAS:AKAO, NAS:RPTP, NAS:VSAR, OTCPK:SXMDF, NAS:ZIOP, NAS:MESO, NAS:IMMU, NAS:CLLS, OTCPK:PHMMF, NAS:PGNX, NAS:ACRS, NAS:CRSP, OTCPK:BIESF, NAS:EDIT, NYSE:MYOV, NAS:ADRO, NAS:JNCE, NAS:NDRM, NAS:XBIT » details
Traded in other countries:AMU.Germany,
AMAG Pharmaceuticals Inc is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The Company markets Makena; Feraheme, Injection for Intravenous ("IV") use; and MuGard, Mucoadhesive Oral Wound Rinse.

Founded in 1981, AMAG Pharmaceuticals uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging.

Top Ranked Articles about AMAG Pharmaceuticals Inc

Steven Cohen Buys AMAG Pharmaceuticals Company focuses on development of regenerative medicine
On July 25, Steven Cohen (Trades, Portfolio) of Point72 Asset Management gained a new holding with AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 3.64
AMAG's Forward PE Ratio is ranked higher than
93% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. AMAG: 3.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 4.86
AMAG's Price-to-Owner-Earnings is ranked higher than
90% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 31.38 vs. AMAG: 4.86 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMAG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.58  Med: 11.17 Max: 23.22
Current: 4.86
4.58
23.22
PB Ratio 0.83
AMAG's PB Ratio is ranked higher than
95% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. AMAG: 0.83 )
Ranked among companies with meaningful PB Ratio only.
AMAG' s PB Ratio Range Over the Past 10 Years
Min: 0.68  Med: 2.47 Max: 18.97
Current: 0.83
0.68
18.97
PS Ratio 1.55
AMAG's PS Ratio is ranked higher than
92% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. AMAG: 1.55 )
Ranked among companies with meaningful PS Ratio only.
AMAG' s PS Ratio Range Over the Past 10 Years
Min: 1.48  Med: 6.72 Max: 505.93
Current: 1.55
1.48
505.93
Price-to-Free-Cash-Flow 3.46
AMAG's Price-to-Free-Cash-Flow is ranked higher than
95% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 24.12 vs. AMAG: 3.46 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMAG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.27  Med: 23.12 Max: 1335.26
Current: 3.46
3.27
1335.26
Price-to-Operating-Cash-Flow 3.40
AMAG's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. AMAG: 3.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMAG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.21  Med: 23.01 Max: 1268.5
Current: 3.4
3.21
1268.5
EV-to-EBIT 15.69
AMAG's EV-to-EBIT is ranked higher than
59% of the 320 Companies
in the Global Biotechnology industry.

( Industry Median: 21.73 vs. AMAG: 15.69 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -602.3  Med: -5.8 Max: 87.5
Current: 15.69
-602.3
87.5
EV-to-EBITDA 7.08
AMAG's EV-to-EBITDA is ranked higher than
78% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. AMAG: 7.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -148.3  Med: -5.75 Max: 367.1
Current: 7.08
-148.3
367.1
Current Ratio 2.30
AMAG's Current Ratio is ranked lower than
69% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. AMAG: 2.30 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.65  Med: 6.77 Max: 36.2
Current: 2.3
1.65
36.2
Quick Ratio 2.18
AMAG's Quick Ratio is ranked lower than
67% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. AMAG: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 6.32 Max: 36.15
Current: 2.18
1.4
36.15
Days Inventory 123.42
AMAG's Days Inventory is ranked higher than
53% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. AMAG: 123.42 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 121.63  Med: 441.37 Max: 1713.48
Current: 123.42
121.63
1713.48
Days Sales Outstanding 63.37
AMAG's Days Sales Outstanding is ranked lower than
53% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. AMAG: 63.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.4  Med: 49.36 Max: 581.14
Current: 63.37
27.4
581.14
Days Payable 11.50
AMAG's Days Payable is ranked lower than
87% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. AMAG: 11.50 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 11.5  Med: 130.3 Max: 2881.25
Current: 11.5
11.5
2881.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.30
AMAG's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. AMAG: -16.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7  Med: -7.6 Max: 0.7
Current: -16.3
-28.7
0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.55
AMAG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 3.58 vs. AMAG: 0.55 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMAG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.3 Max: 9.7
Current: 0.55
0.52
9.7
Price-to-Median-PS-Value 0.23
AMAG's Price-to-Median-PS-Value is ranked higher than
93% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. AMAG: 0.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMAG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 1.18 Max: 53.21
Current: 0.23
0.22
53.21
Earnings Yield (Greenblatt) % 6.38
AMAG's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. AMAG: 6.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMAG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 4.75 Max: 6.8
Current: 6.38
1.1
6.8

More Statistics

Revenue (TTM) (Mil) $532.1
EPS (TTM) $ -0.11
Beta0.79
Short Percentage of Float29.94%
52-Week Range $17.92 - 36.83
Shares Outstanding (Mil)34.34

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 646 565 581
EPS ($) 6.12 3.52 3.06
EPS without NRI ($) 6.12 3.52 3.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
Steven Cohen Increases Position in Dynavax Oct 07 2016 
Steven Cohen Buys AMAG Pharmaceuticals Jul 29 2016 
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference Mar 28 2017
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : March... Mar 21 2017
Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for... Mar 20 2017
Two Biotech Catalysts To Watch Right Now: Bioline RX Ltd (BLRX) And AMAG Pharmaceuticals, Inc.... Mar 14 2017
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Mar 06 2017
AMAG Announces Management Changes and New Commercial Appointments Mar 06 2017
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Mar 01 2017
AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study... Feb 27 2017
AMAG PHARMACEUTICALS INC. Financials Feb 24 2017
AMAG Pharmaceuticals, Inc. -- Moody's revises outlook on AMAG to stable, affirms B2 CFR Feb 21 2017
AMAG PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Feb 21 2017
AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Feb 16 2017
AMAG Pharmaceuticals Inks $60M Drug Deal Feb 16 2017
AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 Feb 15 2017
AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates Feb 15 2017
Edited Transcript of AMAG earnings conference call or presentation 14-Feb-17 1:00pm GMT Feb 14 2017
Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics Feb 14 2017
AMAG Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today Feb 14 2017
AMAG Pharmaceuticals reports 4Q loss Feb 14 2017
AMAG Pharmaceuticals reports 4Q loss Feb 14 2017
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... Feb 14 2017
Q4 2016 AMAG Pharmaceuticals Inc Earnings Release - Before Market Open Feb 14 2017
AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors Dec 21 2016
AMAG Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 03 2016
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Oct 27 2016
AMAG Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call and Webcast on... Oct 19 2016
AMAG Pharmaceuticals Announces Achievement of Key Milestones in Next Generation Development Programs... Oct 12 2016
AMAG Pharmaceuticals Appoints Tony Casciano as Senior Vice President of Hematology/Oncology Sales... Sep 07 2016
AMAG Pharmaceuticals to Present at Upcoming Investor Conference Sep 01 2016
AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 09 2016
AMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts Jul 12 2016
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences May 25 2016
AMAG Pharmaceuticals Announces 2016 Analyst Day May 19 2016
AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results May 03 2016
AMAG Pharmaceuticals to Participate in the Deutsche Bank 41st Annual Healthcare Conference Apr 27 2016
AMAG Pharmaceuticals to Host Conference Call on May 3, 2016 at 8:00 a.m. ET to Discuss Financial... Apr 21 2016
AMAG Pharmaceuticals Appoints Edward Myles as Chief Financial Officer Apr 11 2016
AMAG Pharmaceuticals to Participate in 15th Annual Needham Healthcare Conference Apr 06 2016
AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free... Apr 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)